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Evaluation of leukocyte SIRT1 expression  
in women with gestational diabetes mellitus 
(GDM) in the third trimester of pregnancy
Ocena leukocytarnej ekspresji SIRT1 u kobiet ze zdiagnozowaną  
cukrzycą ciążową (GDM) w trzecim trymestrze ciąży
ABSTRACT
Background. Sirtuin 1 (SIRT1), a NAD+-dependent 
deacetylase, has been implicated as a key regulator of 
glucose/lipid metabolism, insulin secretion as well as 
adiponectin production and inflammation in metabolic 
disorders, including type 2 diabetes mellitus (T2DM). 
However, its role in gestational diabetes mellitus (GDM) 
remains widely unknown. Since GDM is associated with 
inflammation, the aim of this study was to determine 
whether leukocyte SIRT1 mRNA expression is altered 
in GDM women in the third trimester of pregnancy, 
and whether this change is correlated with clinical 
characteristics of patients.
Methods. Leukocytes were isolated from the blood 
of GDM (n = 135) and normal glucose tolerant (NGT; 
n = 52) pregnant women. After extracting RNA from 
leukocytes, a quantitative real-time polymerase chain 
reaction (qRT-PCR) approach was performed to assess 
SIRT1 gene expression in these cells. Univariate regres-
sion analyses were applied to investigate correlations 
between SIRT1 expression and clinic parameters of 
patients. 
Results. Leukocyte SIRT1 mRNA was increased 1.7-fold 
in the GDM vs. NGT subjects (p = 0.001) and it positi-
vely correlated with 2 h glucose concentration during 
oral glucose tolerance test (OGTT) in the whole study 
group and negatively correlated with pregnancy age 
in the GDM and NGT groups. The positive association 
was also observed between SIRT1 mRNA and plasma 
high density lipoprotein (HDL) cholesterol level in the 
NGT subjects. 
Conclusions. GDM is accompanied by leukocyte 
SIRT1 mRNA overexpression associated with hyper-
glycemia. Additionally, there is a close and beneficial 
relationship between enhanced leukocyte SIRT1 expres-
sion and increased plasma HDL-cholesterol level during 
normal pregnancy. (Diabet. Klin. 2014; 3, 1: 3–11)
Key words: gestational diabetes mellitus (GDM), 
sirtuin 1 (SIRT1), oxidative stress, inflammation,  
type 2 diabetes mellitus (T2DM)
STRESZCZENIE
Wstęp. Sirtuina 1 (SIRT1) jest NAD+-zależną deacetyla-
zą, która odgrywa istotną rolę w regulacji metabolizmu 
węglowodanów i lipidów, sekrecji insuliny, produkcji 
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adiponektyny oraz stanu zapalnego w chorobach 
metabolicznych, w tym cukrzycy typu 2 (T2DM). Do 
tej pory brak jest informacji o związku leukocytarnej 
SIRT1 z cukrzycą ciążową (GDM). Zważywszy zwią-
zek SIRT1 ze stanem zapalnym, celem badania było 
określenie zmian w poziomie ekspresji SIRT1 mRNA 
w leukocytach kobiet z GDM w trzecim trymestrze 
ciąży i skorelowanie ich z klinicznymi parametrami 
pacjentek. 
Materiały i metody. Leukocyty wyizolowano z krwi 
pobranej od kobiet ciężarnych z GDM (n = 135) oraz 
kobiet ciężarnych z prawidłową gospodarką węglowo-
danową (NGT; n = 52). Po ekstrakcji RNA z leukocytów 
poziom ekspresji SIRT1 mRNA w tych komórkach okre-
ślono metodą ilościowego qRT-PCR. Korelacje między 
ekspresją SIRT1 a klinicznymi parametrami pacjentek 
analizowano z wykorzystaniem regresji jednokrotnych. 
Wyniki. Ekspresja SIRT1 była 1,7-krotnie wyższa 
w leukocytach kobiet z GDM niż w grupie kobiet 
z NGT (p = 0,001) i dodatnio korelowała ze stężeniem 
glukozy w 2. godzinie testu doustnego obciążenia glu-
kozą (OGTT) w całej badanej populacji pacjentek oraz 
ujemnie korelowała z wiekiem ciąży kobiet zarówno 
w grupie GDM, jak i NGT (p < 0,05). Stwierdzono rów-
nież istotną statystycznie dodatnią korelację między 
ekspresją SIRT1 a stężeniem cholesterolu frakcji HDL 
w grupie NGT (p < 0,05). 
Wnioski. GDM towarzyszy podwyższona ekspresja 
SIRT1 w leukocytach, która jest związana z hipergli-
kemią. Ponadto zaobserwowano istnienie bliskiego 
i korzystnego związku między podwyższonymi po-
ziomami ekspresji SIRT1 a cholesterolem frakcji HDL 
u kobiet z prawidłowym przebiegiem ciąży. (Diabet. 
Klin. 2014; 3, 1: 3–11)
Słowa kluczowe: cukrzyca ciążowa (GDM),  
sirtuina 1 (SIRT1), stres oksydacyjny, stan zapalny, 
cukrzyca typu 2 (T2DM)
Introduction
Sirtuin 1 (SIRT1), a nicotine adenine dinucleotide 
(NAD+)-dependent protein deacetylase, is the most 
extensively studied of mammalian silent information 
regulator 2 proteins (sirtuins) in metabolic disorders, 
including type 2 diabetes mellitus (T2DM) [1]. It is 
well known that SIRT1 is broadly distributed in mam-
malian tissues and its transcriptional level is regulated 
in response to calorie restriction or fasting. SIRT1 has 
been implicated in the regulation of glucose and lipid 
metabolism as well as insulin secretion and inflamma-
tion by deacetylating various transcription factors and 
transcriptional co-regulatory proteins in major metabo-
lic tissues. It has been demonstrated that SIRT1 inhibits 
fat storage and increases lipolysis in adipose tissue via 
repression of PPARg (peroxisome proliferator-activated 
receptor gamma), an essential regulator of adipoge-
nesis and fat storage that affects the expression of 
many adipocyte-specific genes [2]. SIRT1 also induces 
gluconeogenesis and inhibits glycolysis in the liver 
by deacetylating PGC-1a (peroxisome proliferator-
-activated receptor gamma coactivator 1 alpha) under 
low-nutrient conditions [3] and, additionally, enhances 
glucose-stimulated insulin secretion in pancreatic b-cells 
through down-regulation of UCP2 (uncoupling prote-
in 2) [4]. In skeletal muscle, under low glucose level, 
SIRT1 deacetylates PGC-1a causing the activation of ge-
nes involved in mitochondrial fatty acid oxidation, elec-
tron transport, and oxidative phosphorylation; thereby 
it can act as a sensor of nutrient adaptation through 
inducing fatty acid oxidation in response to low glucose 
concentration [5]. Furthermore, SIRT1 inhibits inflam-
mation in adipocytes, macrophages, and hepatocytes 
through the suppression of transcriptional activity of 
NF-kB (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1) resulting from deacetylation of 
RelA/p65 subunit of NF-kB [6–9].
GDM is defined as hyperglycemia with onset or first 
recognition during pregnancy that affects from 3% to 
17% of all pregnancies depending on race and ethnicity 
[10]. GDM is associated with numerous and serious 
complications for both mother (i.e. preeclampsia, 
preterm delivery, cesarean section, pregnancy-induced 
hypertension as well as elevated risk of developing 
T2DM and cardiovascular disease after pregnancy) and 
fetus (i.e. prematurity, macrosomia, hypoglycemia, 
jaundice, respiratory distress syndrome, polycythemia, 
and hypocalcemia) [11]. 
Insulin resistance and pancreatic b-cell dysfunction 
are considered as two major determinants of GDM de-
velopment [12]. Although the pathophysiology of GDM 
remains still unclear, several factors associated with 
this metabolic disorder have been identified. Among 
them, increased oxidative stress and inflammation as 
well as hyperleptinemia and hypoadiponectinemia are 
now most recognized [13–19]. Thus, GDM is a highly 
complex process involving multiple factors, and their 
identification along with elucidation of mechanisms 
underlying GDM is a serious challenge. 
Despite the fact that a number of in vitro and in 
vivo studies have shown the link of SIRT1 with T2DM 
[20, 21], no study exists so far on the role of leukocyte 
SIRT1 in GDM, thus, no data are available on its po-
tential association with anthropometric and metabolic 
parameters of diabetic pregnant women. Therefore, we 
sought to determine whether SIRT1 gene expression is 
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altered in leukocytes of the GDM women in the third 
trimester of pregnancy and whether this change is 
correlated with clinical characteristics of patients. In 
the current study, we employed leukocytes obtained 
from the GDM patients as the experimental cellular 
model, since these cells are known to play a key role 
in pathogenetic processes linked to diabetes such 
as inflammation. In addition, the use of leukocytes 
allowed circumventing the invasive and non-ethical 
procedures involved in taking metabolic tissue samples 
from pregnant women. 
Material and methods
Subjects
This study compared GDM women in the third 
trimester of pregnancy (24–33 weeks) with pregnant 
women with similar characteristics but without GDM. 
One hundred thirty five women with GDM and 52 pre-
gnant women with NGT (control group) were recruited 
to the study from the Diabetological Medical Center 
“OmniMed” in Lodz, Poland. 
All women underwent a 75 g oral glucose toleran-
ce test (OGTT). GDM was diagnosed according to the 
criteria established by the Hyperglycemia and Adverse 
Pregnancy Outcomes (HAPO) study (at least one value 
is met or exceeded of the following thresholds during 
the 75 g OGTT: fasting plasma glucose 92 mg/dL, 
1 h plasma glucose 180 mg/dL, or 2 h plasma glu-
cose 153 mg/dL) [10]. The inclusion criteria were the 
following: 
 — diagnosis of GDM according to the criteria set by 
the HAPO study;
 — Caucasian ethnic background;
 — age range between 18 and 44 years;
 — no family history of diabetes within first-degree re-
latives;
 — no GDM in a previous pregnancy;
 — absence of pre-pregnancy diabetes;
 — absence of concomitant systemic disease (chronic 
or acute or infectious);
 — no treatment with insulin or oral hypoglyce-
mic agents.
The diet and exercise were not controlled before 
overnight fast. All clinical investigations were conduc-
ted in accordance with the guidelines of the Declaration 
of Helsinki and approved by the Ethical Committee of 
the Medical University of Lodz (No. RNN-186-11-KF 
from 20.09.2011). Informed consent was obtained 
from all participating subjects. 
Clinical measurements 
The information on maternal age and pre-pregnan-
cy weight were collected from medical records. The 
weight and height of patients during pregnancy were 
measured using standard methods, and body weight 
gain as well as pre-pregnancy body mass index (BMI), 
expressed as weight before pregnancy divided by 
squared height (kg/m2), were calculated. Gestational 
age was established based on the last menstrual pe-
riod. Systolic (SBP) and diastolic (DBP) blood pressure 
were also measured using an electronic monitor, after 
10 minutes of rest in a sitting position. 
Blood samples were collected from the patients 
between 7.30 a.m. and 9.30 a.m. after a 12-hour 
overnight fast. Serum triglycerides (TGs), and HDL- and 
LDL-cholesterol levels were determined by enzymatic 
colorimetric methods with the triglyceride GPO-PAP and 
the Total Cholesterol CHOD-PAP kits (Roche Diagnostics, 
Mannheim, Germany). The oral glucose tolerance test 
(OGTT) was carried out with the standardized 75 g glu-
cose solution. The glycated hemoglobin (HbA1C) was me-
asured by a latex enhanced turbidimetric immunoassay 
using specific monoclonal antibodies. The biochemical 
assays were carried out on COBAS INTEGRA analyzer (Ro-
che, SA). The concentration of C-reactive protein (CRP) 
was determined by turbidimetric assay with the use of 
the cassette COBAS INTEGRA C-Reactive Protein (Latex) 
according to the manufacturer’s instructions (Roche 
Diagnostics GmbH, Mannheim, Germany). Plasma insulin 
was quantified using Elecsys insulin assay (Roche Diagno-
stics GmbH, Mannheim, Germany). Insulin resistance and 
b-cell function were estimated by homeostasis model 
assessment HOMA-IR and HOMA-B, respectively [22].
HOMA-IR = [fasting insulin (mU/mL) × fasting 
glucose (mg/dL)] / 405
HOMA-B = [360 × fasting insulin (mU/mL)]/  
/[fasting glucose (mg/dL) – 63]
To assess insulin sensitivity, the quantitative insulin 
sensitivity check index (QUICKI-IS) was calculated as fol-
lows: QUICKI-IS = 1/[log (I0) + log (G0)], where I0 is the 
fasting plasma insulin concentration (µU/mL) and G0 is 
the fasting blood glucose concentration (mg/dL) [23].
RNA Extraction and Quantitative Real-Time PCR
Leukocytes were isolated from heparinized blood 
of the patients according to previously described pro-
cedure [24]. Total RNA was extracted from leukocytes 
using commercially available acid-phenol reagent (Tri-
-Reagent® Solution, Ambion, USA) according to the 
manufacturer’s instructions. RNA concentration was 
quantified using a LAMBDA 25 UV spectrophotome-
ter (PerkinElmer, UK). RNA quality and integrity were 
determined through the UV260/280 ratio. Four micro-
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gram of RNA was converted to cDNA in the presence 
of (dT)18 primer and RevertAid™ H Minus M-MuLV 
reverse transcriptase, according to the manufacturer’s 
protocol (Fermentas, Lithuania). The cDNA was diluted 
10-fold, and 2 mL of cDNA was used to perform qRT-
-PCR using Maxima™ SYBR Green/ROX qPCR Master Mix 
(2X) (Thermo Scientific, USA) and specific primers for 
SIRT1 (forward: 5’-GCTCGCCTTGCTGTAGACTT-3’ and 
reverse: 5’-TGTGACAGAGAGATGGCTGG-3’) and for gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
a housekeeping gene (forward: 5’-GGTGGTCTCCTCTGA-
CTTCAACA-3’and reverse: 5’-GTTGCTGTAGCCAA-
ATTCGTTGT-3’). Amplification was carried out on 
7500 Real Time PCR System (Applied Biosystems, USA) 
with initial denaturation at 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 s, 60°C for 60 s. All samples 
were run in duplicate. Specificity of the product was 
assessed from the melting curve analysis.
Following baseline correction, the fluorescence 
threshold level was set during the exponential phase 
of PCR amplification to generate the threshold cycle 
(Ct) value for each amplification curve. The DCt value 
between SIRT1 target and endogenous control GAPDH 
was calculated as: DCt = Ct(SIRT1) - Ct(GAPDH). The expres-
sion changes between the GDM and NGT groups were 
expressed as DDCt and calculated in the following man-
ner: DDCt = DCt (GDM) - DCt (NGT). The fold change value 
between the two groups was determined as 2-DDCt [25].
Statistical analysis
The distribution of analyzed data was checked by 
the Shapiro-Wilk test. Variables with distribution diffe-
rent than normal were transformed logarithmically to 
examine whether they have a log-normal distribution. 
Differences between variables were calculated using the 
Student’s t test (in the case of normally and log-normally 
distributed data) or the non-parametric Mann-Whitney 
U (Wilcoxon) test (in the case of non-Gaussian distri-
bution data). The correlations between SIRT1 mRNA 
expression and each clinical parameter value were 
determined by the nonparametric test of Spearman’s 
rank correlation coefficient. The P value < 0.05 was 
considered as statistically significant. Data are expressed 
as mean value ± standard deviation (SD). Statistical 
analysis was performed using a commercially available 
statistical software package (Statistica version 10.0, 
StatSoft, Poland, license no AXAP301E504323AR-B).
Results
Subjects’ characteristics
The clinical characteristics of 135 GDM and 52 NGT 
pregnant women are presented in Table 1. As expected, 
maternal plasma glucose concentrations at 0 h, 1 h 
and 2 h during 75 g OGTT as well as HbA1C levels were 
significantly higher in the GDM group compared with 
the NGT controls (p < 0.05). Additionally, the GDM 
patients had markedly lower plasma HDL-cholesterol 
levels than the NGT controls (p < 0.05). No significant 
differences existed in both maternal and gestational 
age, blood pressure (SBP and DBP), and the parame-
ters of maternal adiposity (i.e. pre- and pregnancy 
BMI, body weight gain), lipid metabolism (i.e. TGs, 
LDL-cholesterol and total cholesterol), inflammation 
(CRP), insulin resistance/sensitivity (i.e. insulin level, 
HOMA-IR/QUICKI-IS), and insulin secretion (HOMA-B) 
between the two groups (p > 0.05).
Leukocyte SIRT1 mRNA expression  
and correlations
The alterations in leukocyte SIRT1 gene expression 
in the GDM (n = 135) vs. the NGT (n = 52) subjects were 
determined by qRT-PCR. The SIRT1 mRNA level in these 
cells was significantly higher in the GDM group compared 
with the control group (0.016 ± 0.010 vs. 0.011 ± 0.008, 
p = 0.001 as assessed by the non-parametric Mann-
-Whitney U test) with a 1.7-fold up-regulation (Fig. 1). 
To better describe the relationship between 
SIRT1 and GDM, we evaluated the association of 
SIRT1 gene expression with individual clinical para-
meters of patients given in Table 1. Univariate correla-
tion analyses with the use of the Spearman rank test 
revealed that SIRT1 mRNA positively associated with 
2 h OGTT glucose in the whole study group (r = 0.16, 
p = 0.035) (Tab. 2, Fig. 2A) and negatively correlated 
with pregnancy age both in the GDM and NGT pre-
gnant women (r = -0.22, p = 0.015 and r = -0.32, 
p = 0.027, respectively) as well as the entire study 
group (r = -0.20, p = 0.008) (Tab. 2, Fig. 2B–2D). 
There was also the significant positive association of 
SIRT1 mRNA with plasma HDL-cholesterol level in the 
NGT group (r = 0.30, p = 0.039) (Tab. 2, Fig. 2E). There 
were no correlations between leukocyte SIRT1 gene 
expression and other measured variables (Tab. 2).
Discussion
To the best of our knowledge, it is the first study 
concerning the evaluation of leukocyte SIRT1 mRNA 
expression in the GDM group vs. the NGT controls 
and its correlations with clinical characteristics of the 
patients, in an attempt to investigate the potential 
significance of SIRT1 in GDM.
The group of 135 pregnant women with GDM 
and 52 NGT pregnant women at the third trimester of 
gestation was included in the study. The GDM women 
had significantly higher post-load glucose and HbA1C 
levels and lower HDL-cholesterol concentration. 
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In the current study, we found a 1.7-fold increase 
in leukocyte SIRT1 mRNA in the GDM women compared 
with the NGT pregnant control in the third trimester 
of pregnancy, suggesting the existence of a linkage of 
GDM to a change in SIRT1 at its gene expression. The-
se results are in contrast to previous studies showing 
reduced SIRT1 expression in various cells obtained 
from diabetic patients as well as in several obese and 
T2DM animal experimental models. For instance, Song 
et al. [20] reported leukocyte SIRT1 down-regulation 
in T2DM patients aged 45–75 years from the control 
non-diabetic group, who differed in several clinical pa-
rameters, among others BMI. SIRT1 mRNA and protein 
levels were also significantly decreased in epididymal fat 
from insulin resistance obese and db/db diabetic mice 
[26]. Moreover, Sun et al. [27] showed markedly decre-
ased SIRT1 protein level in the gastrocnemius muscle of 
mice with impaired glucose tolerance compared to NGT 
mice. Additionally, the authors provided evidence that 
SIRT1 was directly involved in the modulation of insulin 
sensitivity as a negative regulator of protein tyrosine 
phosphatase 1 B (PTP1B) transcription at the chromatin 
level. Recent studies in this field have supported the 
concept that reduced SIRT1 gene and protein expres-
sion is linked to enhanced insulin resistance of subjects 
[28]. Taking into account the aforementioned studies, 
it may be hypothesized that the elevated leukocyte 
SIRT1 expression in the diabetic pregnant women ob-
served in our study is not related to the clinical variab-
Figure 1. Boxplots of SIRT1 mRNA expression in the NGT 
(n = 52) and GDM (n = 135) groups. Middle line: median; 
box: interquartile range; whisker: range (excluding outliers); 
p = 0.001 compared with the NGT group by the Mann-
-Whitney U test
Table 1. Clinical characteristics of the NGT and GDM groups
Parameter NGT group (n = 52) GDM group (n = 135) p
Age (year) 30.98 ± 4.58 30.96 ± 4.77 0.920a
Pregnancy age (week) 28.57 ± 2.45 28.28 ± 2.48 0.438b
Pre-pregnancy BMI [kg/m2] 25.38 ± 5.02 27.00 ± 6.04 0.099b
Body weight gain [kg] 8.93 ± 4.41 8.50 ± 4.66 0.283b
TGs [mg/dL] 201.97 ± 67.93 206.50 ± 60.58 0.460a
Total cholesterol [mg/dL] 266.25 ± 43.11 259.81 ± 43.40 0.345a
HDL-cholesterol [mg/dL] 82.04 ± 17.34 74.77 ± 15.14 0.008a*
LDL-cholesterol [mg/dL] 146.53 ± 36.08 147.16 ± 41.32 0.888a
HbA1C [%] 5.28 ± 0.24 5.40 ± 0.28 0.008
a*
Glucose 0 h [mg/dL] 81.16 ± 6.29 86.97 ± 13.55 0.004b*
Glucose 1 h [mg/dL] 147.82 ± 31.76 179.15 ± 25.29 < 0.001b**
Glucose 2 h [mg/dL] 135.33 ± 21.76 162.03 ± 23.62 < 0.001b**
SBP [mm Hg] 122.02 ± 12.53 125.11 ± 14.68 0.210a
DBP [mm Hg] 72.96 ± 9.61 74.36 ± 10.77 0.465a
CRP [mg/dL] 4.59 ± 5.44 4.57 ± 4.09 0.557b
Insulin [µIU/mL] 11.82 ± 17.41 10.98 ± 7.28 0.867a
HOMA-IR 2.21 ± 3.43 2.20 ± 1.66 0.059b
HOMA-B 176 ± 97 181 ± 122 0.739a
QUICKI-IS 0.36 ± 0.04 0.35 ± 0.06 0.059b
SIRT1 0.011 ± 0.008 0.016 ± 0.010 0.001b**
BMI — body mass index; CRP — C reactive protein; DBP — diastolic blood pressure; HbA1C — glycated hemoglobin; HDL — high-density lipoprotein;  
HOMA-B — homeostasis model assessment of b-cell function; HOMA-IR — homeostasis model assessment of insulin resistance; HR — heart rate;  
LDL — low-density lipoprotein; SBP — systolic blood pressure; QUICKI-IS — quantitative insulin sensitivity check index; TGs — triglycerides. Data represent 
the mean ± SD 
*p < 0.01; **p < 0.001 as compared to control as assessed by the Student t test (a) or the Mann-Whitney U test (b) for normally or log-normally and non-
normally distributed data, respectively
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les such as age, obesity, and insulin resistance of the 
patients since the GDM and NGT groups were similar 
in term of maternal age as well as the parameters of 
maternal adiposity (i.e. pre- and pregnancy BMI, body 
weight gain) and insulin resistance/sensitivity (i.e. in-
sulin level, HOMA-IR/QUICKI-IS). 
The diet calorie restriction and physical activity are 
proved to be major stimulus for a change in SIRT1 ex-
pression in the insulin-dependent tissues [29]. However, 
12 h fasting of the subjects during the current study 
appears to be too short to detect increased leukocyte 
SIRT1 in the GDM women [29]. Additionally, since the 
NGT and GDM pregnant women enrolled in this stu-
dy did not received any recommendations regarding 
exercise and diet before the overnight fast, thus the 
two groups of patients did not differ between each 
other in this respect, the impact of these factors on 
leukocyte SIRT1 overexpression in the GDM group 
cannot be considered.
Although alterations in leukocyte SIRT1 expression 
have not been yet addressed in GDM, they might be 
related to hyperglycemic conditions, particularly, since 
the significant positive correlation between leukocyte 
SIRT1 mRNA and 2 h OGTT glucose was found in 
the present study. Growing evidence links GDM to 
hyperglycemia-induced oxidative stress, which appe-
ars when there is an imbalance between generation 
of reactive oxygen species (ROS) and its clearance 
by the antioxidant defense systems [13, 30]. Several 
mechanisms underlying this phenomenon have been 
proposed, including the polyol pathway, formation of 
advanced glycation end products (AGEs), the hexosa-
mine pathway, activation of protein kinase C (PKC), 
and enhanced ROS production in the mitochondria 
[13]. In the last few years, a number of in vitro and in 
vivo studies have been published on the protective role 
of SIRT1 overexpression against oxidative stress. For 
example, Hasegawa et al. [31] demonstrated SIRT1 up-
-regulation with the enhancement of catalase expres-
sion in renal tubular cells under ROS-stimulated condi-
tions. Additionally, low to moderate (2.5- to 7.5-fold) 
cardiac-specific SIRT1 overexpression in transgenic mice 
protected the heart against oxidative stress through 
an increase of catalase expression by the forkhead box 
O proteins (FoxO)-dependent mechanism [32]. Interest-
ingly, a greater increase in SIRT1 expression (12.5-fold) 
induced cardiomyopathy [32]. SIRT1 protective function 
against hyperglycemia-induced oxidative stress was 
also reported in pancreatic beta cells [33]. Taking into 
account these findings, it is reasonable to assume that 
leukocyte SIRT1 overexpression under hyperglycemia in 
the GDM women might be a regulatory adaptation of 
Table 2. Univariate correlations of SIRT1 expression with clinical characteristic of patients
Parameter SIRT1  
whole group
SIRT1  
NGT group
SIRT1  
GDM group
r p r p r p
Age (year) 0.05 0.513 0.18 0.226 0.00 0.968
Pregnancy age (week) –0.26 < 0.001* –0.32 0.027* –0.22 0.015*
Pre-pregnancy BMI [kg/m2] 0.02 0.806 –0.10 0.476 0.02 0.809
Body weight gain [kg] –0.11 0.140 –0.11 0.437 –0.10 0.235
TGs [mg/dL] –0.01 0.947 –0.22 0.133 0.07 0.402
Total cholesterol [mg/dL] 0.09 0.252 0.06 0.664 0.13 0.136
HDL-cholesterol [mg/dL] 0.01 0.926 0.30 0.039* –0.03 0.716
LDL-cholesterol [mg/dL] 0.10 0.163 –0.04 0.789 0.16 0.069
HbA1C [%] –0.09 0.219 –0.08 0.572 –0.17 0.057
Glucose 0 h [mg/dL] –0.01 0.946 –0.01 0.927 –0.06 0.492
Glucose 1 h [mg/dL] 0.17 0.067 0.10 0.595 –0.05 0.671
Glucose 2 h [mg/dL] 0.16 0.035* 0.02 0.902 0.03 0.722
SBP [mm Hg] 0.11 0.130 0.01 0.926 0.11 0.192
DBP [mm Hg] 0.04 0.605 –0.17 0.257 0.07 0.407
CRP [mg/dL] –0.02 0.832 –0.16 0.284 0.02 0.838
Insulin [µIU/mL] 0.08 0.279 –0.07 0.656 0.11 0.236
HOMA–IR 0.05 0.537 –0.10 0.528 0.05 0.543
HOMA–B 0.14 0.073 0.06 0.725 0.18 0.053
QUICKI–IS –0.05 0.537 0.10 0.528 –0.05 0.543
r- and p-values are given. Abbreviations are indicated in Table 1. *Significant correlation as assessed by the Spearman’s correlation method
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the maternal organism to enhanced oxidative stress du-
ring diabetic pregnancy. Unfortunately, oxidative stress 
markers that could fully confirm this hypothesis have 
not been determined in this study. Therefore further 
studies are clearly needed in this field to completely 
elucidate the relationship of leukocyte SIRT1 with 
hyperglycemia-mediated oxidative stress in the GDM 
women in the third trimester of pregnancy.
Another interesting finding in the current study is 
the positive correlation of leukocyte SIRT1 mRNA with 
plasma HDL-cholesterol in the NGT group. The plasma 
HDL-cholesterol level is currently believed to be a major 
determinant of susceptibility to coronary atherosclero-
sis since its concentration inversely correlated with at-
herosclerotic cardiovascular disease risk in humans [34]. 
It is well-known that anti-atherogenic HDL-cholesterol 
Figure 2. The correlations between leukocyte SIRT1 mRNA expression and 2 h OGTT glucose plasma concentration in the entire 
study group (A), gestational age in the NGT and GDM groups (B and C) as well as in the whole study population (D), and plasma 
HDL-cholesterol level in the NGT controls (E)
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properties stem from its anti-oxidant, anti-thrombotic, 
anti-inflammatory, vasodilatory, and endothelial repair 
activities as well as its capacity to mediate cellular 
cholesterol efflux through acting as primary acceptor, 
thereby promoting reverse cholesterol transport (RCT) 
from the artery wall and peripheral tissue to the liver 
[35]. The relationship of SIRT1 with HDL metabolism 
and RCT has been found. In this regard, SIRT1 has been 
identified as a positive regulator of liver X receptors 
(LXRs), belonging to the nuclear receptors superfamily, 
which modulate key genes involved in HDL metabolism 
and RCT, including the ATP-binding cassette transporter 
A1 (ABCA1) [36]. Consistent with this, SIRT1 knockout 
mice exhibited abnormal cholesterol homeostasis due 
to decreased ABCA1 expression resulting in a reduction 
of RCT as well as HDL-cholesterol [36]. Given the above, 
it is possible that the positive correlation of leukocyte 
SIRT1 mRNA with plasma HDL-cholesterol concentration 
in the NGT group observed in our study might reflect 
the protective role of leukocyte SIRT1 overexpression 
against atherosclerotic cardiovascular diseases in 
healthy pregnant women in the third trimester of 
pregnancy through an increase of HDL-cholesterol 
formation resulting, at least partially, from enhanced 
RCT. However, the precise mechanism responsible for 
such association remains to be elucidated in the future.
Another remarkable observation of this study is 
that leukocyte SIRT1 expression correlated inversely 
with pregnancy age in both the GDM and NGT pre-
gnant women. However, the causes and effects of 
this relationship are impossible to determine in the 
current study since no information exists on this topic 
in the literature. Thus, further research are required in 
this fields to explain why leukocyte SIRT1 expression 
decreases with increasing gestational age of pregnant 
women with and without GDM. In this regard, changes 
in metabolic and endocrine factors should be conside-
red since they play a central role in the course of normal 
and diabetic pregnancy.
Conclusions
To date, there is a paucity of data on SIRT1 and 
GDM. This study provides, for the first time, five novel 
valuable data information. First, leukocyte SIRT1 mRNA 
was markedly increased in the GDM vs. NGT women in 
the third trimester of pregnancy, suggesting that GDM 
might affect changes in SIRT1 at its gene expression 
level. Second, leukocyte SIRT1 gene expression was 
correlated positively with the plasma glucose con-
centration in the GDM women, implying that higher 
SIRT1 expression could reflect the hyperglycemic state 
in diabetic patients. In this regard, the major limitation 
of our study was the lack of measurements of oxidative 
stress markers that would help to clarify the link between 
hyperglycemia-mediated oxidative stress and leukocyte 
SIRT1 overexpression in the GDM women. Third, leukocyte 
SIRT1 expression was correlated positively with HDL- 
-cholesterol in the NGT pregnant women, suggesting that 
enhanced expression of this enzyme could have a benefi-
cial effect on increased HDL-cholesterol production during 
normal pregnancy. Fourth, leukocyte SIRT1 expression was 
correlated inversely with pregnancy age in both the GDM 
and NGT pregnant women. However, the establishment 
of the causes and effects of this association requires 
further studies. Fifth, leukocytes seem to be a convenient 
experimental model to detect changes in SIRT1 expression 
and to assess the potential mechanisms involved in these 
alterations since there is a serious ethical problem linked 
to any invasive method used to obtain metabolic tissue 
samples from pregnant women.
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